Aviex Technologies LLC was founded
to develop a novel vaccine platform delivery technology for infectious diseases.

Product Pipeline

AVIEX - AV-0211W: Clostridiodes difficile (C. difficile) PROPHYLACTIC Vaccine

Aviex selected the bacterium C. difficile as the initial vaccine candidate for its enhanced YS1646 vaccine platform delivery technology. The YS1646-based multi-modality vaccines targeting either CdTA or CdTB can rapidly achieve protection in a mouse model of lethal C. difficile infection. Protective patient immunity is induced in a substantially shorter period of time than other candidate vaccines have demonstrated.

  • There are no effective licensed prophylactic vaccines on the market.
  • C. difficile infects the intestinal mucosa resulting in inflammation and cellular damage to the colon, leading to potentially severe complications, including enterocolitis with toxic megacolon, and possible death.
  • An estimated 500,000 cases are diagnosed in the U.S. annually, resulting in more than 29,000 deaths yearly.
  • This Infection is hospital-associated and most often occurs in people with prolonged antibiotic use.
  • The infection has an estimated 10 to 60 percent recurrence, depending on the patient`s risk factors.
  • Treatment of C. difficile infection (CDI) results in an estimated annual cost to the US healthcare system of approximately $4.8 billion, and is increasing.

PRESENTATIONS

June 18-19, 2020 ANNUAL CONFERENCE ON VACCINOLOGY RESEARCH (ACVR) CONFERENCE.
Multi-Modal Vaccination Targeting Clostridioides difficile Based on a Chromosomally Integrated, Attenuated Salmonella Typhimurium Vector Protects Mice from Challenge
Presenter: Kaitlin Winter, PhD - McGill University, Montreal, Quebec, Canada


PUBLICATIONS

Vaccination against Clostridium difficile by Use of an Attenuated Salmonella enterica Serovar Typhimurium Vector (YS1646) Protects Mice from Lethal Challenge
Kaitlin Winter, Li Xing, Audrey Kassardjian, Brian J. Ward; Vincent B. Young, Editor
Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada
Published in Infection and Immunity, August 2019 Volume 87 Issue 8.
https://iai.asm.org/content/87/8/e00089-19

Watch for new 2023 manuscripts.

AVIEX - AV-0213W: SCHISTOSOMA mansoni (S.mansoni) PROPHYLACTIC Vaccine

This is a major public health threat in many parts of the world. S. mansoni is a life threatening disease of the gut caused by a flat worm parasite. It is only exceeded by malaria as a parasitic pathogen affecting humans. Although some anti-parasiticals are an effective treatment, resistance is increasing. There are an estimated 700 million people on three continents at risk for this devastating disease. There is no commercial vaccine for any human schistosome. The disease affects low and middle income countries, and over 250,000,000 individuals are already infected. Early data generated with the Aviex S.mansoni prophylactic candidate have exceeded expectations and demonstrated a significant reduction of egg and worm burden; when the vaccine is administered using the multi-modality regimen.

PRESENTATIONS

American Society of Tropical Medicine and Hygiene (ASTMH) Nov. 20-24, 2019 in National Harbor, MC

PUBLICATIONS

Evaluation of the immunogenicity of a chromosomally integrated Salmonella Typhimurium vaccine vector expressing Schistosoma mansoni Cathepsin B
Adam S. Hassan, Sébastien Houle, Lydia Labrie, Charles M. Dozois, Brian J. Ward, Momar Ndao
Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada
To Be Published in NPJ: Vaccine To Be Published: January 2023

Vaccination against the digestive enzyme Cathepsin B using a YS1646 Salmonella enterica Typhimurium vector provides almost complete protection against Schistosoma mansoni challenge in a mouse model
Adam S. Hassan, Nicholas H. Zelt, Dilhan J. Perera, Momar Ndao, Brian J. Ward
Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada
Published in PLOS Neglected Tropical Diseases Published: December 2, 2019
https://doi.org/10.1371/journal.pntd.0007490

AVIEX - AV-0214W: SCHISTOSOMA mansoni (S.mansoni) THERAPEUTIC Vaccine

Schistosomiasis is an important fresh-water-borne parasitic disease caused by trematode worms of the genus Schistosoma. With > 250 million people infected worldwide and approximately 800 million people at risk, the World Health Organization considers schistosomiasis to be the most important human helminth infection. Several prophylactic non-living vaccines are in pre-clinical and clinical development, but only one has been assessed for therapeutic effect in an animal model with modest results. Live attenuated Salmonella have multiple potential advantages as vaccine vectors.

We have engineered an attenuated Salmonella enterica Typhimurium strain (YS1646) to produce a vaccine that targets the parasite digestive enzyme Cathepsin B (CatB). A multi-modality immunization schedule was used in chronically infected mice that included three oral (PO) doses of this CatB-bearing YS1646 strain on days one, three, and five as well as an intramuscular (IM) dose of recombinant CatB on day one. Parasite burden (worm count, intestinal and liver egg numbers) were 46.5 – 50.3% lower than in control animals 1 month post-vaccination and relative reductions further increased to 63.9 – 73.3% at 2 months. Serum anti-CatB IgG increased significantly after vaccination with the development of a more balanced TH1/TH2 pattern of response (ie: a shift in the IgG1:IgG2c ratio). Compared to control animals, a broad and robust CatB-specific cytokine/chemokine response was seen in splenocytes isolated 1 month post-vaccination. A vaccine that has both prophylactic and therapeutic activity would be ideal for use in conjunction with mass treatment campaigns with praziquantel in schistosome-endemic countries.

PRESENTATIONS

June 18-19, 2020 ANNUAL CONFERENCE ON VACCINOLOGY RESEARCH (ACVR) CONFERENCE.

Therapeutic Application of a YS1646 Salmonella Typhimurium Vectored Vaccine in Mice Chronically-Infected with Schistosoma mansoni
Presenter: Adam S. Hassan, PhD - McGill University, Montreal, Quebec, Canada

PUBLICATIONS

Therapeutic activity of a Salmonella-vectored Schistosoma mansoni vaccine in a mouse model of chronic infection
Adam S. Hassan a,b, Dilhan J. Perera b,c, Brian J. Ward a,b,c, Momar Ndao a,b,c
Department of Microbiology & Immunology, McGill University, Montreal, Canada
Infectious Diseases and Immunity in Global Health (IDIGH), Research Institute of the McGill University Health Centre, Montreal, Canada
Division of Experimental Medicine, McGill University, Montreal, Canada
Published in Elsevier Ltd: VACCINE Published: September 15, 2021
https://www.sciencedirect.com/science/article/pii/S0264410X21010513

AVIEX - AV 0222W SCHISTOSOMA mansoni (S.mansoni)

In the current work, we report the construction of a chromosomally integrated, single-copy CatB recombinant YS1646 Salmonella Typhimurium strain. Vaccination with this novel vector resulted in significant reductions in parasite burden in a murine model. Multimodal immunization led to robust humoral and cellular immune responses with a balanced TH1/TH2 profile. To our knowledge, this is the first report of a chromosomally integrated Salmonella-vectored vaccine for schistosomiasis.

PUBLICATIONS

Salmonella Typhimurium expressing chromosomally integrated Schistosoma mansoni Cathepsin B protects against schistosomiasis in mice
Adam S. Hassan, Se'bastien Houle, Lydia Labrie, Dilhan J. Perera, Charles M. Dozois, Brian J. Ward & Momar Ndao
Department of Microbiology and immunology, McGill University Montreal, Quebec, Canada
Published in NPJ VACCINES Published:February 27, 2023
https://www.nature.com/articles/s41541-023-00599-w

AVIEX - AV-0216W: CRYPTOSPORIDIUM parvum (C.parvum) PROPHYLACTIC Vaccine

This global pathogen causes severe and prolonged diarrhea in healthy people, and has a high mortality rate in people with weakened immune systems (i.e. HIV). Both humans and animals are affected by the disease, and it causes life-long stunting when it infects young children. Aviex has achieved POC in the immunogenicity study for this non-clinical candidate.

PUBLICATIONS

Watch for 2024 new manuscript.